LT4 logo

Liquidia DB:LT4 Stock Report

Last Price

€14.38

Market Cap

€1.1b

7D

3.2%

1Y

130.4%

Updated

22 Mar, 2024

Data

Company Financials +

LT4 Stock Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.

LT4 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Liquidia Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Liquidia
Historical stock prices
Current Share PriceUS$14.38
52 Week HighUS$14.60
52 Week LowUS$5.39
Beta0.14
1 Month Change11.30%
3 Month Change39.61%
1 Year Change130.37%
3 Year Change565.74%
5 Year Changen/a
Change since IPO315.61%

Recent News & Updates

Recent updates

Shareholder Returns

LT4DE PharmaceuticalsDE Market
7D3.2%1.1%1.2%
1Y130.4%-23.8%5.5%

Return vs Industry: LT4 exceeded the German Pharmaceuticals industry which returned -26.1% over the past year.

Return vs Market: LT4 exceeded the German Market which returned 4.9% over the past year.

Price Volatility

Is LT4's price volatile compared to industry and market?
LT4 volatility
LT4 Average Weekly Movement8.6%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.0%
10% least volatile stocks in DE Market2.5%

Stable Share Price: LT4's share price has been volatile over the past 3 months.

Volatility Over Time: LT4's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2004145Roger Jeffshttps://www.liquidia.com

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion.

Liquidia Corporation Fundamentals Summary

How do Liquidia's earnings and revenue compare to its market cap?
LT4 fundamental statistics
Market cap€1.14b
Earnings (TTM)-€72.59m
Revenue (TTM)€16.17m

70.6x

P/S Ratio

-15.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LT4 income statement (TTM)
RevenueUS$17.49m
Cost of RevenueUS$2.89m
Gross ProfitUS$14.60m
Other ExpensesUS$93.10m
Earnings-US$78.50m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.03
Gross Margin83.49%
Net Profit Margin-448.89%
Debt/Equity Ratio97.3%

How did LT4 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.